The grades of six Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
PharmAthene, Inc.’s (AMEX:PIP) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). PharmAthene develops biological and chemical defense products. For more information, get Portfolio Grader’s complete analysis of PIP stock.
ARIAD Pharmaceuticals, Inc.’s (NASDAQ:ARIA) ratings are looking better this week, moving up to a B from last week’s C. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) gets a higher grade this week, advancing from a C last week to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. Shares of NBIX have increased 9.3% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
The rating of Array BioPharma (NASDAQ:ARRY) moves up this week, rising from a C to a B. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
This week, Insmed Incorporated’s (NASDAQ:INSM) ratings are up from a C last week to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.